The committee observed the absence of concrete regulatory intervention on pricing and insurance coverage that continue to make CGMs and essential diabetic medicines unaffordable.
Simple ethical design
The committee observed the absence of concrete regulatory intervention on pricing and insurance coverage that continue to make CGMs and essential diabetic medicines unaffordable.
